Clonal Evolution in Patients with Hormone Receptor (HR) Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors
Conclusion
Clonal evolution might differ significantly between metastatic breast cancer patients with HR positive and HER-2 negative disease treated with chemotherapy or CDK4/6 inhibitors. These results should be confirmed in larger patient cohorts. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 25, 2022 Category: Cancer & Oncology Source Type: research
Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma
Conclusion: Comprehensive genetic testing for predictive biomarkers (e.g., PD-L1, MSI/dMMR, tTMB, EBV) to identify patient subgroups most eligible for immunotherapy is of particular importance in aGC, especially in patients that are refractory to conventional chemotherapy. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 25, 2022 Category: Cancer & Oncology Source Type: research
PD-1 Blockade Elicits Ongoing Remission in Two Cases of Refractory Epstein-Barr Virus Associated Metastatic Gastric Carcinoma
Conclusion:
Comprehensive genetic testing for predictive biomarkers (e.g. PD-L1, MSI/dMMR, tTMB, EBV) to identify patient subgroups most eligible for immunotherapy is of particular importance in advanced g astric cancer, especially in patients that are refractory to conventional chemotherapy. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 25, 2022 Category: Cancer & Oncology Source Type: research
Transparency on Platelet Transfusion in Routine Cancer Care: The Key for Optimal Blood Usage?
Conclusions: Platelet transfusions in a haematological/oncology setting are highly individual in terms of the total number of t ransfusions and transfusion intervals. The majority of all PC transfusions was given to only a small group of patients. Continuous, structured real-world data collection/evaluation and benchmarking with data from more centres seems essential in determining specific needs in this vulnerable patient g roup, assessing quality of transfusion practices, determining effectiveness and anticipating future demand for platelets and a sustainable blood supply. So far, not all relevant data are collected rout...
Source: Oncology Research and Treatment - February 16, 2022 Category: Cancer & Oncology Source Type: research
Five-Fraction Stereotactic Radiotherapy for Brain Metastases: A Single-Institution Experience on Different Dose Schedules
Conclusion
The results of this retrospective analysis suggest that FFSRT for BrM seems to be safe and feasible. Our results also underline that a total dose lower than 30 Gy in 5 fractions should not be used due to the expected minor LC. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 16, 2022 Category: Cancer & Oncology Source Type: research
Chronic Cutaneous Disorders Are Associated with a More Favorable Disease Presentation and Outcome in Patients with Hodgkin Lymphoma
Conclusion: Our results demonstrated that among patients with Hodgkin lymphoma, pre-existing cutaneous symptoms are associated with a limited stage disease, absence of B-symptoms and favourable prognosis. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 8, 2022 Category: Cancer & Oncology Source Type: research
Pancreatic Ductal Adenocarcinoma: New Insights into the Actions of Vitamin A
Background: Pancreatic ductal adenocarcinoma (PDAC) is a gland-forming malignancy arising in the pancreas. It is estimated that in developed countries the incidence of PDAC will continue to rise, and PDAC is now the fourth leading cause of cancer-related deaths in the USA. The mortality of PDAC patients closely parallels the incidence rate, as this malignancy generally remains asymptomatic until it reaches an advanced stage.
Summary: The poor prognosis results from the aggressive nature of the tumor, late detection, and resistance to chemotherapy and radiotherapy. Retinoids, vitamin A (retinol) and its metabolites, such a...
Source: Oncology Research and Treatment - February 7, 2022 Category: Cancer & Oncology Source Type: research
Risk and Incidence of Infection with Bevacizumab in Non-Small Cell Lung Cancer Patients: A Meta-analysis
Conclusions: Th e use of bevacizumab is not associated with a significantly higher risk of infections in NSCLC patients. These data provide reassurance regarding the risk of incidence of infection in patients with NSCLC receiving bevacizumab. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 3, 2022 Category: Cancer & Oncology Source Type: research
Society Bulletins
Oncol Res Treat 2022;45:74 –78 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 1, 2022 Category: Cancer & Oncology Source Type: research
PharmaNews
Oncol Res Treat 2022;45:68 –73 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 1, 2022 Category: Cancer & Oncology Source Type: research
Nintedanib und Docetaxel beim Adenokarzinom der Lunge
Oncol Res Treat 2022;45:66 –67 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 1, 2022 Category: Cancer & Oncology Source Type: research
First-in-Class-Therapie mit Sacituzumab Govitecan
Oncol Res Treat 2022;45:64 –65 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 1, 2022 Category: Cancer & Oncology Source Type: research
Ibrutinib: signifikanter OS-Vorteil gegen über FCR
Oncol Res Treat 2022;45:63 –63 (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - February 1, 2022 Category: Cancer & Oncology Source Type: research
Discoidin Domain Receptor 2: A New Target in Cancer
Background: Discoidin domain receptor is a new and unique type of receptor tyrosine kinases, which binds to collagen, the main compose of an extracellular matrix. DDR1 was identified to mediate cell aggregation, and dysregulation of DDR2 has also been shown to be involved in tumor pathogenesis, although its role in cancer development and progression remains controversial.Summary: Abnormal expression and mutations of DDR2 have been reported in several cancer types and its participation in different aspects of tumor progression, including proliferation, migration, invasion, metastasis, epithelial-mesenchymal transition, and ...
Source: Oncology Research and Treatment - January 24, 2022 Category: Cancer & Oncology Source Type: research
A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study)
Conclusion: The rapid change of the treatment landscape, the limited use of bevacizumab and interferon in 1st line and the duration of 1st line treatment jeopardized BERAT trial recruitment. The small number of patients is a major limitation of our trial. Our observation indicated the poor prognosis in progressive patients and the limited efficacy of TKI or mTOR inhibitors in 2nd line treatment. (Source: Oncology Research and Treatment)
Source: Oncology Research and Treatment - January 19, 2022 Category: Cancer & Oncology Source Type: research
